Johnson & Johnson (NYSE:JNJ) Maintains Strong Position with UBS's "Buy" Rating

UBS maintains a "Buy" rating for Johnson & Johnson (NYSE:JNJ) and raises its price target from $180 to $190. JNJ's recent financial performance exceeded expectations, leading to an increase in full-year 2025 earnings guidance. Despite a slight decrease in stock price, JNJ's market capitalization and trading volume indicate significant investor interest and confidence in its future growth.

Johnson & Johnson (NYSE:JNJ) is a well-known healthcare company that operates in the pharmaceutical, medical devices, and consumer health sectors. It competes with other major players like Pfizer and Merck. On July 17, 2025, UBS maintained its "Buy" rating for JNJ, reflecting confidence in the company's future performance. At that time, JNJ's stock was priced at $162.74.

UBS also raised its price target for JNJ from $180 to $190, indicating optimism about the stock's potential growth. This decision aligns with JNJ's recent financial performance, as the company reported quarterly earnings that exceeded expectations. As highlighted by Benzinga, this strong performance led to an increase in JNJ's full-year 2025 earnings guidance.

Currently, JNJ is trading at $163.07, showing a slight decrease of approximately 1.04% or $1.71. The stock has fluctuated between a low of $162.30 and a high of $164.56 during the day. Over the past year, JNJ's stock has reached a high of $169.99 and a low of $140.68, reflecting some volatility in its price.

JNJ's market capitalization is approximately $392.36 billion, indicating its significant size and influence in the healthcare industry. The trading volume for JNJ is 1,646,844 shares, suggesting active investor interest. Despite the recent price decrease, the positive earnings report and raised price target by UBS may attract more investors to the stock.